Literature DB >> 34174442

Controlling CRISPR with small molecule regulation for somatic cell genome editing.

Namita Khajanchi1, Krishanu Saha2.   

Abstract

Biomedical research has been revolutionized by the introduction of many CRISPR-Cas systems that induce programmable edits to nearly any gene in the human genome. Nuclease-based CRISPR-Cas editors can produce on-target genomic changes but can also generate unwanted genotoxicity and adverse events, in part by cleaving non-targeted sites in the genome. Additional translational challenges for in vivo somatic cell editing include limited packaging capacity of viral vectors and host immune responses. Altogether, these challenges motivate recent efforts to control the expression and activity of different Cas systems in vivo. Current strategies utilize small molecules, light, magnetism, and temperature to conditionally control Cas systems through various activation, inhibition, or degradation mechanisms. This review focuses on small molecules that can be incorporated as regulatory switches to control Cas genome editors. Additional development of CRISPR-Cas-based therapeutic approaches with small molecule regulation have high potential to increase editing efficiency with less adverse effects for somatic cell genome editing strategies in vivo.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Enter keywords here

Mesh:

Substances:

Year:  2021        PMID: 34174442      PMCID: PMC8753294          DOI: 10.1016/j.ymthe.2021.06.014

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   12.910


  127 in total

1.  The studies on the toxicity mechanism of environmentally hazardous natural (IAA) and synthetic (NAA) auxin--The experiments on model Arabidopsis thaliana and rat liver plasma membranes.

Authors:  Katarzyna Hąc-Wydro; Michał Flasiński
Journal:  Colloids Surf B Biointerfaces       Date:  2015-04-09       Impact factor: 5.268

2.  CRISPR gene-editing tested in a person for the first time.

Authors:  David Cyranoski
Journal:  Nature       Date:  2016-11-24       Impact factor: 49.962

3.  Quest to use CRISPR against disease gains ground.

Authors:  Heidi Ledford
Journal:  Nature       Date:  2020-01       Impact factor: 49.962

4.  Control of CRISPR-Cas9 with small molecule-activated allosteric aptamer regulating sgRNAs.

Authors:  Bingqian Lin; Yuan An; Lingyan Meng; Huimin Zhang; Jia Song; Zhi Zhu; Wen Liu; Yanling Song; Chaoyong Yang
Journal:  Chem Commun (Camb)       Date:  2019-10-08       Impact factor: 6.222

Review 5.  Degrons in cancer.

Authors:  Bálint Mészáros; Manjeet Kumar; Toby J Gibson; Bora Uyar; Zsuzsanna Dosztányi
Journal:  Sci Signal       Date:  2017-03-14       Impact factor: 8.192

Review 6.  Therapeutic genome editing: prospects and challenges.

Authors:  David Benjamin Turitz Cox; Randall Jeffrey Platt; Feng Zhang
Journal:  Nat Med       Date:  2015-02       Impact factor: 53.440

7.  Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing.

Authors:  Qiurong Ding; Alanna Strong; Kevin M Patel; Sze-Ling Ng; Bridget S Gosis; Stephanie N Regan; Chad A Cowan; Daniel J Rader; Kiran Musunuru
Journal:  Circ Res       Date:  2014-06-10       Impact factor: 17.367

8.  Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization.

Authors:  Serif Senturk; Nitin H Shirole; Dawid G Nowak; Vincenzo Corbo; Debjani Pal; Alexander Vaughan; David A Tuveson; Lloyd C Trotman; Justin B Kinney; Raffaella Sordella
Journal:  Nat Commun       Date:  2017-02-22       Impact factor: 14.919

9.  Tamoxifen Activation of Cre-Recombinase Has No Persisting Effects on Adult Neurogenesis or Learning and Anxiety.

Authors:  Peter Rotheneichner; Pasquale Romanelli; Lara Bieler; Sebastian Pagitsch; Pia Zaunmair; Christina Kreutzer; Richard König; Julia Marschallinger; Ludwig Aigner; Sébastien Couillard-Després
Journal:  Front Neurosci       Date:  2017-02-01       Impact factor: 4.677

10.  Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch.

Authors:  Benjamin L Oakes; Dana C Nadler; Avi Flamholz; Christof Fellmann; Brett T Staahl; Jennifer A Doudna; David F Savage
Journal:  Nat Biotechnol       Date:  2016-05-02       Impact factor: 54.908

View more
  2 in total

1.  The CRISPR-Cas system as a tool for diagnosing and treating infectious diseases.

Authors:  Juan Lou; Bin Wang; Junwei Li; Peng Ni; Yuefei Jin; Shuaiyin Chen; Yuanlin Xi; Rongguang Zhang; Guangcai Duan
Journal:  Mol Biol Rep       Date:  2022-07-20       Impact factor: 2.742

Review 2.  Tailoring Cardiac Synthetic Transcriptional Modulation Towards Precision Medicine.

Authors:  Eric Schoger; Sara Lelek; Daniela Panáková; Laura Cecilia Zelarayán
Journal:  Front Cardiovasc Med       Date:  2022-01-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.